Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty

被引：16

作者：

Hilal, Talal ^{[1
]}

Betcher, Jeffrey A. ^{[2
]}

Leis, Jose F. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol & Med Oncol, 5881 E Mayo Blvd, Phoenix, AZ 85054 USA

[2] Mayo Clin, Dept Pharm, Phoenix, AZ USA

来源：

CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2018年 / 13卷 / 04期

关键词：

CLL; Ibrutinib; Idelalisib; Venetoclax; Drug costs; Pharmacoeconomics; financial toxicity; OPEN-LABEL; INITIAL THERAPY; CANCER DRUGS; IBRUTINIB; RITUXIMAB; COST; IDELALISIB; CYCLOPHOSPHAMIDE; FLUDARABINE; MULTICENTER;

D O I：

10.1007/s11899-018-0461-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices. The cost of therapy for CLL has increased substantially since the introduction of oral therapies. This increase in cost is caused by multiple factors including cost of drug development, alternate reimbursement patterns, lack of transparency, and lack of free market competition. Oral therapies for CLL have dramatically increased costs for both patients and payers. Some solutions to overcome this include value-based pricing, transparency, and legal action that allow Medicare to negotiate drug prices with manufacturers.

引用

页码：237 / 243

页数：7

共 41 条

[31] Next-generation multiple myeloma treatment: a pharmacoeconomic perspective [J].

Rajkumar, S. Vincent ;

Harousseau, Jean Luc .

BLOOD, 2016, 128 (24) :2757-2764

[32] Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels [J].

Shanafelt, Tait D. ;

Borah, Bijan J. ;

Finnes, Heidi D. ;

Chaffee, Kari G. ;

Ding, Wei ;

Leis, Jose F. ;

Chanan-Khan, Asher A. ;

Parikh, Sameer A. ;

Slager, Susan L. ;

Kay, Neil E. ;

Call, Tim G. .

JOURNAL OF ONCOLOGY PRACTICE, 2015, 11 (03) :252-+

[33] Chronic Lymphocytic Leukemia-The Price of Progress [J].

Shanafelt, Tait D. ;

Gunderson, Heidi ;

Call, Timothy G. .

ONCOLOGIST, 2010, 15 (06) :601-602

[34]

SHARMAN JP, 2014, J CLIN ONCOL S, V32

[35] The High Cost of Cancer Drugs and What We Can Do About It [J].

Siddiqui, Mustaqeem ;

Rajkumar, S. Vincent .

MAYO CLINIC PROCEEDINGS, 2012, 87 (10) :935-943

[36]

Siegel R. L., 2017, CA-CANCER J CLIN, V67, P30, DOI [10.3322/caac.21387, DOI 10.3322/CAAC.21442]

[37] Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study [J].

Stilgenbauer, Stephan ;

Eichhorst, Barbara ;

Schetelig, Johannes ;

Coutre, Steven ;

Seymour, John F. ;

Munir, Talha ;

Puvvada, Soham D. ;

Wendtner, Clemens-Martin ;

Roberts, Andrew W. ;

Jurczak, Wojciech ;

Mulligan, Stephen P. ;

Boettcher, Sebastian ;

Mobasher, Mehrdad ;

Zhu, Ming ;

Desai, Monali ;

Chyla, Brenda ;

Verdugo, Maria ;

Enschede, Sari Heitner ;

Cerri, Elisa ;

Humerickhouse, Rod ;

Gordon, Gary ;

Hallek, Michael ;

Wierda, William G. .

LANCET ONCOLOGY, 2016, 17 (06) :768-778

[38] Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia [J].

Tam, Constantine S. ;

O'Brien, Susan ;

Wierda, William ;

Kantarjian, Hagop ;

Wen, Sijin ;

Do, Kim-Anh ;

Thomas, Deborah A. ;

Cortes, Jorge ;

Lerner, Susan ;

Keating, Michael J. .

BLOOD, 2008, 112 (04) :975-980

[39] In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs [J].

Tefferi, Ayalew ;

Rajkumar, S. Vincent ;

Gertz, Morie A. ;

Kyle, Robert A. ;

Kantarjian, Hagop ;

Allison, James ;

Bast, Robert C., Jr. ;

Cortes, Jorge ;

Fidler, Isaiah J. ;

Freireich, Emil ;

Gutterman, Jordan ;

Hong, Waun Ki ;

Hortobagyi, Gabriel N. ;

Mendelsohn, John ;

Strong, Louise C. ;

Ueno, Naoto T. ;

LeMaistre, Charles A. ;

Baker, Lawrence H. ;

Lawrence, Theodore S. ;

Abkowitz, Jan L. ;

Deeg, H. Joachim ;

Estey, Elihu ;

Lyman, Gary H. ;

Adamson, John W. ;

Advani, Ranjana Hira ;

Coutre, Steven ;

Greenberg, Peter ;

Link, Michael P. ;

Rosenberg, Saul A. ;

Antman, Karen H. ;

Bennett, John M. ;

Benz, Edward J., Jr. ;

Canellos, George Peter ;

Daley, George Q. ;

DeAngelo, Daniel J. ;

Fuchs, Charles ;

Handin, Robert I. ;

Kantoff, Philip W. ;

Steensma, David P. ;

Stone, Richard ;

Winer, Eric P. ;

Berliner, Nancy ;

Handin, Robert I. ;

Bertino, Joseph ;

Bhatia, Ravi ;

Bhatia, Smita ;

Erba, Harry P. ;

Bhojwani, Deepa ;

Blanke, Charles D. ;

Bloomfield, Clara D. .

MAYO CLINIC PROCEEDINGS, 2015, 90 (08) :996-1000

[40] Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia [J].

Thompson, Philip A. ;

Tam, Constantine S. ;

O'Brien, Susan M. ;

Wierda, William G. ;

Stingo, Francesco ;

Plunkett, William ;

Smith, Susan C. ;

Kantarjian, Hagop M. ;

Freireich, Emil J. ;

Keating, Michael J. .

BLOOD, 2016, 127 (03) :303-309

← 1 2 3 4 5 →